{"id":"bortezomib-cyclophosphamide-thalidomide-dexamethasone","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Infection"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"40-60","effect":"Fatigue"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL325041","moleculeType":"Small molecule","molecularWeight":"384.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bortezomib is a proteasome inhibitor that blocks NF-κB signaling and induces apoptosis in myeloma cells. Cyclophosphamide is an alkylating agent causing DNA damage. Thalidomide is an immunomodulatory drug (IMiD) that enhances T-cell proliferation and has anti-angiogenic properties. Dexamethasone is a corticosteroid that enhances the anti-myeloma effects of the other agents.","oneSentence":"This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing tumor necrosis factor, and providing immunomodulatory effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:19.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed or relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT00871013","phase":"PHASE2","title":"Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2009-03","conditions":"Myeloma","enrollment":160},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT01539083","phase":"PHASE3","title":"Velcade (Bortezomib) Consolidation After Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-01-13","conditions":"Multiple Myeloma","enrollment":256},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT03759093","phase":"PHASE2, PHASE3","title":"CURATE.AI Optimized Modulation for Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-09-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT02559154","phase":"PHASE4","title":"Modified Bortezomib-based Combination Therapy for Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT03402295","phase":"PHASE3","title":"Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation","status":"COMPLETED","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2009-06-15","conditions":"Multiple Myeloma, Effects of Chemotherapy","enrollment":311},{"nctId":"NCT00574080","phase":"PHASE3","title":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01971658","phase":"PHASE3","title":"Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2013-10","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT01537861","phase":"EARLY_PHASE1","title":"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-06","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT01134484","phase":"PHASE3","title":"VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Michele Cavo","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":480},{"nctId":"NCT00531453","phase":"PHASE2","title":"A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":98},{"nctId":"NCT01114048","phase":"PHASE2","title":"Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2010-03","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00438841","phase":"PHASE2","title":"Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma","status":"UNKNOWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Velcade, genuxal, decadron"],"phase":"phase_3","status":"active","brandName":"Bortezomib, cyclophosphamide, thalidomide, dexamethasone","genericName":"Bortezomib, cyclophosphamide, thalidomide, dexamethasone","companyName":"Grupo de Estudos Multicentricos em Onco-Hematologia","companyId":"grupo-de-estudos-multicentricos-em-onco-hematologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing tumor necrosis factor, and providing immunomodulatory effects. Used for Multiple myeloma (newly diagnosed or relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}